PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy
PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy
Quite a few PTC Therapeutics, Inc. (NASDAQ:PTCT) insiders sold their shares over the past year, which may be a cause for concern. When evaluating insider transactions, knowing whether insiders are buying versus if they selling is usually more beneficial, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more.
在過去的一年中,不少PTC Therapeutics, Inc.(納斯達克股票代碼:PTCT)內部人士出售了股票,這可能令人擔憂。在評估內幕交易時,了解內部人士是買入還是賣出通常更有利,因爲後者可能有多種解釋。但是,如果有許多內部人士出售,股東應該進行更多調查。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
儘管我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但我們確實認爲密切關注內部人士的所作所爲是完全合乎邏輯的。
The Last 12 Months Of Insider Transactions At PTC Therapeutics
PTC Therapeutics 過去 12 個月的內幕交易
The CEO & Director, Matthew Klein, made the biggest insider sale in the last 12 months. That single transaction was for US$274k worth of shares at a price of US$27.15 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$24.15). So it is hard to draw any strong conclusion from it.
首席執行官兼董事馬修·克萊因進行了過去12個月中最大規模的內幕出售。這筆單筆交易是價值27.4萬美元的股票,每股價格爲27.15美元。雖然我們通常不喜歡看到內幕銷售,但更令人擔憂的是是否以較低的價格進行銷售。一線希望是,這種拋售發生在最新價格(24.15美元)之上。因此,很難從中得出任何強有力的結論。
All up, insiders sold more shares in PTC Therapeutics than they bought, over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
總而言之,去年內部人士出售的PTC Therapeutics股票比他們買入的還要多。您可以看到下圖所示的去年的內幕交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。
Insiders At PTC Therapeutics Have Sold Stock Recently
PTC Therapeutics的內部人士最近出售了股票
We've seen more insider selling than insider buying at PTC Therapeutics recently. In total, insiders sold US$981k worth of shares in that time. On the other hand we note Chief Financial Officer Pierre Gravier bought US$199k worth of shares , as previously mentioned . Generally this level of net selling might be considered a bit bearish.
最近,我們在PTC Therapeutics看到的內幕賣出多於內幕買入。在此期間,內部人士總共出售了價值98.1萬美元的股票。另一方面,我們注意到首席財務官皮埃爾·格拉維爾購買了價值199萬美元的股票,如前所述。通常,這種淨賣出水平可能被認爲有點看跌。
Insider Ownership
內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. PTC Therapeutics insiders own about US$45m worth of shares. That equates to 2.5% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。PTC Therapeutics內部人士擁有價值約4500萬美元的股票。這相當於該公司的2.5%。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。
So What Does This Data Suggest About PTC Therapeutics Insiders?
那麼,這些數據對PTC Therapeutics內部人士有何啓示呢?
The insider sales have outweighed the insider buying, at PTC Therapeutics, in the last three months. Despite some insider buying, the longer term picture doesn't make us feel much more positive. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing PTC Therapeutics. Be aware that PTC Therapeutics is showing 5 warning signs in our investment analysis, and 2 of those can't be ignored...
在過去的三個月中,PTC Therapeutics的內幕銷售超過了內幕收購。儘管有一些內幕買盤,但長期前景並不能使我們感到更加樂觀。儘管內部人士確實擁有股票,但他們並不擁有大量股票,他們一直在拋售。購買前我們會謹慎行事!除了了解正在進行的內幕交易外,確定PTC Therapeutics面臨的風險也是有益的。請注意,PTC Therapeutics在我們的投資分析中顯示了5個警告信號,其中2個不容忽視...
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。